Octreotate-Lu-177-DOTA-Tyr-3.

The article describes the cases of six patients with neuroendocrine tumours, who developed hormonal crises after receiving the antineoplastic agent octreotate-Lu-177-DOTA-Tyr-3 based on a study in the Netherlands by B. de Keizer et al, published in the April 2008 issue of the "European Journal of Nuclear Medicine and Molecular Imaging." The patients exhibited symptoms such as flushing, nausea and hypokalaemia during the course of the treatment. Octreotide therapy was discontinued in one patient after a year.